Annual Meeting

AM17 Daily News Saturday

Issue link: http://read.uberflip.com/i/832413

Contents of this Issue

Navigation

Page 0 of 119

Dr. Siddhartha Mukherjee to Address ASCO Opening Session F ew people have contrib- uted more to the public's understanding of cancer than Siddhartha Mukher- jee, MD, DPhil, assistant profes- sor of medicine specializing in the research of myelodysplastic syndromes, myeloma, and lym- phoma at Columbia University Medical Center. Dr. Mukherjee's Pulitzer Prize– winning book, The Emperor of All Maladies: A Biography of Cancer, was named one of the 100 best nonfiction books of all time by Time Magazine and was devel- oped into an Emmy-nominated television documentary series by Ken Burns. Since that book's publication, Dr. Mukherjee has published The Laws of Medicine: Field Notes from an Uncertain Science and The Gene: An Intimate History. The latter, named one of The Washington Post's 10 Best Books of 2016, maps the history of the human genome and "its surprising influence on our lives, personalities, identities, fates, and choices." Dr. Mukherjee brings this perspective to the 2017 ASCO Annu- al Meeting, where he will serve as the guest speaker at this year's Opening Session. He sat down with the ASCO Daily News for an interview before this year's Annual Meeting. ASCO Daily News: Can you describe your Opening Session address? Dr. Mukherjee: I have tentatively chosen to speak about four patients: one of the first patients to receive trastuzumab for breast cancer, a patient who received one of the first successful target- ed therapies, one patient treated with immunotherapy, and lastly someone who has benefited from secondary prevention. I will use these four cases and talk about the human stories be- hind them to illustrate the advances and also the challenges of can- cer care. I will use these four cases to talk about one idea: how to detect cancer at the earliest possible phase without risking overdi- agnosis and treatment, which is the major challenge of cancer care. ASCO Daily News: You recently authored a piece in The New Yorker about 'deep learning' systems and the future of cancer diagnosis. How is deep learning impacting cancer care? How will it influence oncology in the future? Dr. Mukherjee: The New Yorker piece on artificial intelligence was meant to be provocative. One reason that deploying personalized therapies may not work well at times is that by the time we deploy them, we may be too late. At such late points, tumors might have become highly evolved. So one place that deep learning can be helpful is to diagnose cancer at an earlier stage. Deep-learning tools might be able to pick up a breast cancer lesion at an earlier stage, or a melanoma before human eyes could easily diagnose it. That Dr. Carl H. June Named the 2017 David A. Karnofsky Memorial Award and Lecture Recipient C arl H. June, MD, the Richard W. Vague Profes- sor in Immunotherapy at the Perelman School of Medicine, University of Penn- sylvania, has been honored with the 2017 David A. Karnof- sky Memorial Award and Lec- ture for pioneering the use of engineered T cells in targeted cancer therapy and for leaving a lasting mark on the field of cancer immunotherapy. In an interview with the ASCO Daily News, Dr. June com- mented on the personal signifi- cance of this recognition and credited his colleagues at the University of Pennsylvania, his family, and the patients who volunteered to participate in clinical trials. "I am honored to be receiving an award named after Dr. Kar- nofsky, who made so many dis- coveries that are still used in our daily practice," Dr. June said. "I'm very proud to represent the field of cancer immunotherapy in general, and those develop- ing CAR-T cells in particular, in accepting this award, which symbolizes the recent advances and pending [U.S. Food and Drug Administration] approvals of targeted therapies of cancer using engineered T cells." Early Beginnings in Adoptive Immunotherapy Dr. June's early beginnings in cancer immunotherapy were marked by an accidental finding that led to an unex- pected turn in his research. In 1992, his postdoctoral student Dr. Bruce Levine was working on developing a T-cell culture system for HIV but repeatedly failed to isolate viral particles from T-cell cultures of patients with late-stage HIV/AIDS. Puz- zled and frustrated by his stu- dent's inability to perform this straightforward task, Dr. June repeated the experiment, only to obtain the same results. His team later attributed the absence of viral particles in T- cell cultures of patients with HIV to the downregulation of CCR5, the HIV-1 co-receptor on CD4 cells. 1 This accidental find- ing sparked Dr. June's interest in adoptive transfer of T cells in patients with HIV/AIDS and resulted in two landmark publi- cations in Science. "Chance can have a large determination in career paths and, in my case, is perhaps best remembered by the quote from Yogi Berra, who said, 'When you come to a fork in the road, take it,'" Dr. June said. Adoptive Immunotherapy for Cancer and HIV Infection In the past decade, Dr. June's work has been focused on studying the potential use of MEETING COVERAGE Challenges of Treating Elderly Patients With Myeloma 20A In Briefs 23A Value in Cancer Care 1B Lifestyle Interventions in Cancer Treatment 35B Global Health Track Highlights 1C Physician Wellness Skills 33C Must-See Saturday and Sunday Sessions 1D PHYSICIAN-AUTHORED Expert Editorials ASCO-AACI's Best Practices in Cancer Clinical Trials Initiative 3A Preventing HPV-Related Cancers 12A Utilization Management in Oncology 18A Opioid Therapy in Patients at Risk for Aberrant Use 1B The Benefits of QOPI ® Certification 12B Changes in WHO Classification of Lymphoid Malignancies 20B Using Computer Assistance to Bridge Gaps Between Trials and Practice 26B The Evolution of Liquid Biopsies in Breast Cancer Management 1C Managing Therapy-Related Late Effects in Childhood Cancer Survivors 16C Cancer Immunotherapy: The End of the Beginning or the Beginning of the End? 18C JGO: Our Voice for Global Oncology 26C Clinical Corner Second-Line Ipilimumab in Metastatic Melanoma 34B Treating ER-Positive, HER2-Negative Metastatic Breast Cancer 32C ASCO NEWS "Why YIA?" Campaign 12A Dr. Barbara L. McAneny Is Running for AMA President 20A Dr. Paulo M. G. Hoff Elected to Brazil's National Academy of Medicine 21A CancerLinQ ® Unites Oncology Care Leaders 22A 'Principles for Patient- Centered Healthcare Reform' 23A 2016 Palliative Care Symposium Highlights 14B Health Policy Fellows Selected 33B ASCO COME HOME Program 33B Virtual Mentors Provide Guidance 34B Guideline: Managing Chronic Pain in Adult Cancer Survivors 3C International Innovation Grants 10C ASCO Medical Oncology In-Training Exam Predicts Success 23C SPECIAL AWARDS Humanitarian Award: Dr. Olufunmilayo I. Olopade 1B Gianni Bonadonna Breast Cancer Award: Dr. Eric P. Winer 1C HIGHLIGHTS DAILY NEWS SATURDAY · J U N E 3, 20 1 7 A See ASCO Opening Session, Page 8A Letter From the Editor John Sweetenham, MD, FRCP, FACP I hope that you are as ex- cited to be in Chicago for the 2017 ASCO An- nual Meeting as I am! The theme of this year's Meeting, "Making a Dif- ference in Cancer Care WITH YOU," is a reminder of why we all gather to- gether every year for this incredible event—to im- prove the lives of those affected by cancer. I have been thinking back to my first ASCO Meeting in Connect with employers and advance your career by visiting the ASCO Career Fair in the Oncology Professionals Hall, Saturday and Sunday from 9:00 AM to 5:00 PM. Attendee Tip of the Day See Karnofsky Award, Page 18A See Letter From the Editor, Page 3A Dr. Carl H. June Dr. Siddhartha Mukherjee Dr. John Sweetenham

Articles in this issue

view archives of Annual Meeting - AM17 Daily News Saturday